These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23027412)

  • 21. Relationship of affect recognition with psychopathology and cognitive performance in schizophrenia.
    Bozikas VP; Kosmidis MH; Anezoulaki D; Giannakou M; Karavatos A
    J Int Neuropsychol Soc; 2004 Jul; 10(4):549-58. PubMed ID: 15327733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cognitive remediation and cognitive assistive technologies in schizophrenia].
    Sablier J; Stip E; Franck N
    Encephale; 2009 Apr; 35(2):160-7. PubMed ID: 19393385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia.
    AhnAllen CG
    Curr Opin Psychiatry; 2012 Mar; 25(2):103-8. PubMed ID: 22262029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic treatment in schizophrenia: the role of computerized neuropsychological assessment.
    Kertzman S; Reznik I; Grinspan H; Weizman A; Kotler M
    Isr J Psychiatry Relat Sci; 2008; 45(2):114-20. PubMed ID: 18982837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive impairment of executive function as a core symptom of schizophrenia.
    Wobrock T; Ecker UK; Scherk H; Schneider-Axmann T; Falkai P; Gruber O
    World J Biol Psychiatry; 2009; 10(4 Pt 2):442-51. PubMed ID: 18609418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of attention in schizophrenia.
    Birkett P; Brindley A; Norman P; Harrison G; Baddeley A
    J Psychiatr Res; 2006 Oct; 40(7):579-88. PubMed ID: 16359710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Learning potential and cognitive remediation in schizophrenia].
    Raffard S; Gely-Nargeot MC; Capdevielle D; Bayard S; Boulenger JP
    Encephale; 2009 Sep; 35(4):353-60. PubMed ID: 19748372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained attention and working memory deficits follow a familial pattern in schizophrenia.
    Giakoumaki SG; Roussos P; Pallis EG; Bitsios P
    Arch Clin Neuropsychol; 2011 Nov; 26(7):687-95. PubMed ID: 21813556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Working memory impairments in first-episode psychosis and chronic schizophrenia.
    Zanello A; Curtis L; Badan Bâ M; Merlo MC
    Psychiatry Res; 2009 Jan; 165(1-2):10-8. PubMed ID: 19046607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neurocognitive deficits in schizophrenia].
    Rund BR
    Tidsskr Nor Laegeforen; 2002 Aug; 122(20):2019-22. PubMed ID: 12555450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Executive functioning component mechanisms and schizophrenia.
    Kerns JG; Nuechterlein KH; Braver TS; Barch DM
    Biol Psychiatry; 2008 Jul; 64(1):26-33. PubMed ID: 18549874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling schizophrenia: uncovering novel therapeutic targets.
    Desbonnet L; O'Tuathaigh CM; Waddington JL
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):667-76. PubMed ID: 23234324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of cognitive functions in animal models of schizophrenia.
    Nikiforuk A
    Pharmacol Rep; 2018 Aug; 70(4):639-649. PubMed ID: 29894866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stimulating the development of drug treatments to improve cognition in schizophrenia.
    Green MF
    Annu Rev Clin Psychol; 2007; 3():159-80. PubMed ID: 17716052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Methods to evaluate cognitive disorders in animal models].
    Navarrete F; Pérez-Ortiz JM; Femenía T; García-Gutiérrez MS; García-Payá ME; Leiva-Santana C; Manzanares J
    Rev Neurol; 2008 Aug 1-15; 47(3):137-45. PubMed ID: 18654968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Schizophrenia: treatment targets beyond monoamine systems.
    Ibrahim HM; Tamminga CA
    Annu Rev Pharmacol Toxicol; 2011; 51():189-209. PubMed ID: 20868275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioral animal models of antipsychotic drug actions.
    Peleg-Raibstein D; Feldon J; Meyer U
    Handb Exp Pharmacol; 2012; (212):361-406. PubMed ID: 23129339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.
    Young JW; Geyer MA
    J Psychopharmacol; 2015 Feb; 29(2):178-96. PubMed ID: 25516372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Animal models of working memory: a review of tasks that might be used in screening drug treatments for the memory impairments found in schizophrenia.
    Dudchenko PA; Talpos J; Young J; Baxter MG
    Neurosci Biobehav Rev; 2013 Nov; 37(9 Pt B):2111-24. PubMed ID: 22464948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The attentional set-shifting test paradigm in rats for the screening of novel pro-cognitive compounds with relevance for cognitive deficits in schizophrenia.
    Denis Goetghebeur PJ; Dias R
    Curr Pharm Des; 2014; 20(31):5060-8. PubMed ID: 24345267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.